FDA amends, rather than rescinds, BMS HCV 'breakthrough'
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb said on 20 May it was able to provide the FDA with additional data that prevented the company from losing another one of its breakthrough therapy designations for one of its daclatasvir-based hepatitis C virus (HCV) regimens.